ROGAINE REVIEW: ADVISORY COMMITTEE CONSIDERS "MEANINGFUL" EFFICACY
This article was originally published in The Tan Sheet
Executive Summary
ROGAINE REVIEW: ADVISORY COMMITTEE CONSIDERS "MEANINGFUL" EFFICACY standard in determining whether Upjohn's prescription baldness product (2% minoxidil) should be available OTC. FDA's Nonprescription Drugs Advisory Committee, supplemented with members of the Dermatologic Drugs and Cardiovascular and Renal Drugs Advisory Committees, met on July 27 and voted 10-4 against recommending Rogaine for over-the-counter use.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning